Advantages

- High Robustness & Reproducibility: Greatly expands the process window for critical process parameters, including differentiation reagent concentrations and cell density, thereby improving robustness and reproducibility.
- High Differentiation Efficiency: Consistently achieves cardiomyocyte differentiation efficiency of ≥90%.
- High Quality: Enables the generation of cardiomyocytes with quality comparable to those of cardiomyocytes produced using conventional protocols.
- Cost-Effective Process: Uses only inexpensive small molecules without the need for costly cytokines.

Current Stage and Key Data

Proof of Concept (PoC) has been completed in a 2D culture, and the utility of the technology has been demonstrated across multiple human iPSC lines.
- Greatly Expanded Process Window: Demonstrated a substantial expansion of the process window of critical process parameters, including differentiation reagent concentrations and cell density, compared with the conventional protocol.
- Dramatically Improved Batch-to-Batch Stability: In multiple parallel batch comparisons with the conventional protocol, the method overcame the large variability in differentiation efficiency observed with the conventional protocol and demonstrated exceptionally high reproducibility.
- High Differentiation Efficiency: Consistently achieved ≥90% cardiomyocyte differentiation efficiency (cTNT-positive cells) across multiple human iPSC lines.
- High-Quality Cardiomyocytes: Comprehensive gene expression and functional analyses confirmed that the generated cardiomyocytes are comparable to those obtained using the conventional protocol.

Partnaring Model

Patent licensing, joint research/development, and technical guidance alliances.
- Potential partners: Regenerative medicine cell manufacturers, drug discovery & toxicity screening assay providers, and developers of cardiac cell therapies.

Background and Technology

Cardiomyocyte differentiation from pluripotent stem cells (iPSCs/ESCs) is highly important for regenerative medicine and drug discovery. However, conventional protocols have suffered from substantial variability in differentiation efficiency across experimental and production batches, as well as among different cell lines. This technology fundamentally addresses this variability by precisely optimizing the timing of early signaling modulation and greatly expanding the process window for differentiation reagent concentrations and cell density, both of which are known to strongly affect differentiation efficiency. This enables the stable, large-scale production of high-quality cardiomyocytes.

Principal Investigator

Hirokazu Akiyama (Graduate School of Engineering, Nagoya University, Tokai National Higher Education and Research System)

Patents and Publications

- Patent pending